Ask most cardiologists what they know about amlodipine and they’ll tell you it is one of the cleanest, most forgiving blood pressure drugs in the formulary. Long half-life, gradual onset, high protein binding that keeps it where it needs to be. Easy to dose, easy to live with. It’s on the WHO’s essential medicines list for a reason. Now ask those same cardiologists what happens to amlodipine when the patient is on a continuous renal replacement circuit, and you will mostly get a shrug. That is not a knock on cardiologists. It is a knock on the entire system of drug development and clinical research, which for decades treated ICU…